Physician profile
Miranda High
NPI 1215529078
$5,174.66
in general payments reported to CMS, 2019-2025
46 companies · $2,380 in 2025
The $2,380 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $527 · 2023: $1,701 · 2024: $567 · 2025: $2,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,885 · Travel and Lodging: $721 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,884.67 |
| Travel and Lodging | $720.89 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $1,166.71 | 2023 | Intracept |
| Madrigal Pharmaceuticals | $376.64 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.12 | 2022-2024 | Relistor |
| Collegium Pharmaceutical, INC. | $281.27 | 2022-2024 | Xtampza, Belbuca, Nucynta |
| Abbvie INC. | $274.76 | 2022-2025 | |
| Abbott Laboratories | $272.46 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Xeris Pharmaceuticals, INC. | $267.46 | 2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $240.22 | 2025 | |
| Recordati_rare_diseases_inc. | $202.79 | 2025 | Isturisa |
| Corcept Therapeutics | $185.72 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $165.75 | 2025 | |
| Abiomed | $112.88 | 2024 | Impella |
| Biohaven Pharmaceutical Holding Company Ltd. | $110.95 | 2022 | |
| Novo Nordisk INC | $87.93 | 2025 | Rybelsus, Ozempic |
| Beta Bionics, INC. | $79.17 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $69.18 | 2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $65.92 | 2025 | Yorvipath |
| Amgen INC. | $62.82 | 2022-2025 | Tepezza |
| Teva Pharmaceuticals USA, INC. | $58.04 | 2022-2024 | Ajovy |
| Nevro Corp. | $56.80 | 2023-2024 | Senza |
| Medtronic, INC. | $54.87 | 2023-2025 | Synchromedii, Inceptiv |
| Sanofi-Aventis U.S. LLC | $48.47 | 2025 | |
| Acella Pharmaceuticals, LLC | $47.99 | 2025 | NP Thyroid 60 |
| Pfizer INC. | $46.21 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $44.34 | 2022-2023 | Ztlido |
| Dexcom, INC. | $41.43 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $36.52 | 2025 | Shingrix, Arexvy |
| Saluda Medical Americas, INC. | $33.11 | 2023-2024 | Evoke Scs, Evoke |
| Esperion Therapeutics, INC. | $31.99 | 2025 | Nexletol |
| Amneal Pharmaceuticals LLC | $31.00 | 2025 | Unithroid |
| Ultragenyx Pharmaceutical INC. | $28.95 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $27.93 | 2022 | |
| Bioventus LLC | $24.99 | 2023 | Gelsyn-3 |
| Astellas Pharma US INC | $24.81 | 2025 | Veozah |
| Spr Therapeutics, INC | $24.00 | 2023 | Sprint Pns System |
| Tandem Diabetes Care, INC. | $21.86 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Idorsia Pharmaceuticals US INC | $20.96 | 2022 | |
| Cequr Corporation | $20.75 | 2025 | Cequr Simplicity |
| Almatica Pharma LLC | $19.67 | 2023 | Gralise |
| Rhythm Pharmaceuticals, INC. | $18.83 | 2025 | Imcivree |
| Lilly USA, LLC | $18.68 | 2022 | |
| Global Blood Therapeutics, INC. | $17.76 | 2022 | |
| Boston Scientific Corporation | $17.64 | 2025 | Wavewriter Alpha Prime 16 |
| Painteq LLC | $14.95 | 2024 | Painteq |
| Merck Sharp & Dohme LLC | $13.35 | 2022 | |
| Currax Pharmaceuticals LLC | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda High listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.